← All indications
Immunoblastic Lymphadenopathy
A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.
Drugs by status
Phase 3 trials (1)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (8)
Organization Involved with Phase 2 Indications (48)
- Spectrum Pharmaceuticals
- Seattle Genetics
- Roche
- Merck
- Genzyme
- BeOne Medicines
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Agios Pharmaceuticals, Inc.
- PharmaMar
- National Cancer Center, Korea
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- Cancer and Leukemia Group B (CALGB)
- Case Western Reserve University
- Cancer Research UK
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- University of Washington
- Korea Cancer Center Hospital
- Northwestern University
- Ohio State University
- Qingdao University
- Rutgers University
- Singapore General Hospital
- Southwest Oncology Group
- Stanford University
- Thomas Jefferson University
- University of Exeter
- University of Medicine and Dentistry of New Jersey
- +18 more
Organization Involved with Phase 1 Indications (19)
- Millennium Pharmaceuticals
- Amgen
- Morphotek
- Arno Therapeutics
- Huazhong University of Science and Technology
- University of Pittsburgh
- AIDS Malignancy Consortium
- Johns Hopkins University
- University of Toronto
- Wake Forest University
- Wayne State University
- Zhengzhou University
- University of Colorado, Denver
- Rush University
- University of Wisconsin
- University of Alabama, Birmingham
- Wuhan Bio-Raid Biotechnology Co, Ltd. China
- SciTech Development, LLC
- St. Jude Children's Hospital
Organization Involved with Other Experimental Indications (1)